

## Drug Policy:

# Monjuvi™ (tafasitamab-cxix)

<b>POLICY NUMBER</b> UM ONC_1412	<b>SUBJECT</b> Monjuvi™ (tafasitamab-cxix)		<b>DEPT/PROGRAM</b> UM Dept	<b>PAGE 1 OF 3</b>
<b>DATES COMMITTEE REVIEWED</b> 09/09/20, 09/08/21, 11/15/21, 02/09/22, 04/13/22, 05/11/22, 07/13/22	<b>APPROVAL DATE</b> July 13, 2022	<b>EFFECTIVE DATE</b> July 29, 2022	<b>COMMITTEE APPROVAL DATES</b> 09/09/20, 09/08/21, 11/15/21, 02/09/22, 04/13/22, 05/11/22, 07/13/22	
<b>PRIMARY BUSINESS OWNER:</b> UM		<b>COMMITTEE/BOARD APPROVAL</b> Utilization Management Committee		
<b>URAC STANDARDS</b> HUM v8: UM 1-2; UM 2-1	<b>NCQA STANDARDS</b> UM 2		<b>ADDITIONAL AREAS OF IMPACT</b>	
<b>CMS REQUIREMENTS</b>	<b>STATE/FEDERAL REQUIREMENTS</b>		<b>APPLICABLE LINES OF BUSINESS</b> Commercial, Exchange, Medicaid	

### I. PURPOSE

To define and describe the accepted indications for Monjuvi (tafasitamab-cxix) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

### II. INDICATIONS FOR USE/INCLUSION CRITERIA

#### A. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

1. When health plan Medicaid coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the [Preferred Drug Guidelines OR](#)
2. When health plan Exchange coverage provisions-including any applicable PDLs (Preferred Drug Lists)-conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the [Preferred Drug Guidelines OR](#)
3. For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the [Preferred Drug Guidelines shall follow NCH L1 Pathways](#)

[\(http://pathways.newcenturyhealth.com/\)](http://pathways.newcenturyhealth.com/) when applicable, otherwise shall follow NCH drug policies AND

4. Continuation requests of previously approved, non-preferred medication are not subject to this provision AND
5. When applicable, generic alternatives are preferred over brand-name drugs AND
6. When there is a documented drug shortage, disease progression, contraindication, or confirmed intolerance to a Preferred drug/regimen, per NCH Policy and Pathway, the available alternative product may be used if deemed medically appropriate and the indication is listed in a standard reference compendia or accepted peer review literature. For a list of current drug shortages, please refer to FDA drug shortage website in the reference section.

#### **B. Diffuse Large B Cell Lymphoma (DLBCL)**

1. Monjuvi (tafasitamab-cxix) may be used in combination with Revlimid (lenalidomide) up to 12 cycles with further continuation as monotherapy for members with
  - a. Relapsed/refractory DLBCL (including transformation from an indolent lymphoma) who are not candidates for a stem cell transplant or have failed a prior stem cell transplant AND
  - b. Receipt of 1-3 prior regimens including a chemoimmunotherapy regimen containing an anti- CD20-targeted therapy (e.g., rituximab, obinituzumab).

### **III. EXCLUSION CRITERIA**

- A. Monjuvi (tafasitamab-cxix) is being used on or after disease progression with the same regimen.
- B. Dosing exceeds single dose limit of Monjuvi (tafasitamab-cxix) 12 mg/kg.
- C. Treatment exceeds the maximum months duration limit of 12 cycles (when used in combination with lenalidomide).
- D. Investigational use of Monjuvi (tafasitamab-cxix) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
  1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
  2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
  3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definition of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of < 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
  4. Whether the experimental design, in light of the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
  5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
  6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.

7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

#### IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

#### V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

#### VI. ATTACHMENTS

- A. None

#### VII. REFERENCES

- A. Salles G, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. *Lancet Oncol.* 2020 Jul;21(7):978-988.
- B. Duell J, et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. *Haematologica.* 2021 Sep 1;106(9):2417-2426.
- C. Nowakowski et al. ASH 2021, abstract 183. Observational, retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- D. Monjuvi prescribing information. MorphoSys US Inc. Boston, MA 2021.
- E. Clinical Pharmacology Elsevier Gold Standard 2022.
- F. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, CO 2022.
- G. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics
- H. Compendium 2022.
- I. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer
- J. Lexi-Drugs. Bethesda, MD 2022.
- K. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol.* 2014 Apr 20;32(12):1277-80.
- L. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
- M. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.